MX9603338A - Uso de sensibilizadores a la insulina para tratar enfermedades renales. - Google Patents

Uso de sensibilizadores a la insulina para tratar enfermedades renales.

Info

Publication number
MX9603338A
MX9603338A MX9603338A MX9603338A MX9603338A MX 9603338 A MX9603338 A MX 9603338A MX 9603338 A MX9603338 A MX 9603338A MX 9603338 A MX9603338 A MX 9603338A MX 9603338 A MX9603338 A MX 9603338A
Authority
MX
Mexico
Prior art keywords
renal diseases
treating renal
insulin sensitisers
human
insulin
Prior art date
Application number
MX9603338A
Other languages
English (en)
Inventor
Robin Edwin Buckingham
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9402624A external-priority patent/GB9402624D0/en
Priority claimed from GB9410214A external-priority patent/GB9410214D0/en
Priority claimed from GBGB9426019.7A external-priority patent/GB9426019D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of MX9603338A publication Critical patent/MX9603338A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un método para el tratamiento y/o profilaxis de enfermedades renales incluyendo nefropatía diabética, glomerulonefritis, esclerosis glomerular, síndrome nefrotico, nefroesclerosis hipertensiva y enfermedad renal de etapa terminal, y microalbuminuria, dicho método comprendiendo la administracion de una cantidad no toxica efectiva de un sensibilizador a la insulina a un ser humano u otro mamífero que necesita el mismo.
MX9603338A 1994-02-10 1995-02-07 Uso de sensibilizadores a la insulina para tratar enfermedades renales. MX9603338A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9402624A GB9402624D0 (en) 1994-02-10 1994-02-10 Novel method
GB9410214A GB9410214D0 (en) 1994-05-21 1994-05-21 Novel method
GBGB9426019.7A GB9426019D0 (en) 1994-12-22 1994-12-22 Novel method
PCT/EP1995/000441 WO1995021608A1 (en) 1994-02-10 1995-02-07 Use of insulin sensitisers for treating renal diseases

Publications (1)

Publication Number Publication Date
MX9603338A true MX9603338A (es) 1997-03-29

Family

ID=27267046

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9603338A MX9603338A (es) 1994-02-10 1995-02-07 Uso de sensibilizadores a la insulina para tratar enfermedades renales.

Country Status (11)

Country Link
EP (1) EP0777469A1 (es)
JP (1) JPH09512249A (es)
CN (2) CN1083715C (es)
AP (1) AP553A (es)
AU (1) AU700826B2 (es)
CA (1) CA2182986A1 (es)
IL (1) IL112590A (es)
MX (1) MX9603338A (es)
SG (1) SG47100A1 (es)
TW (1) TW475896B (es)
WO (1) WO1995021608A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889025A (en) * 1996-05-06 1999-03-30 Reddy's Research Foundation Antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
ZA973848B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them.
US5919782A (en) * 1996-05-06 1999-07-06 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US6372750B2 (en) 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
USRE39266E1 (en) * 1996-07-01 2006-09-05 Dr. Reddy's Laboratories, Limited Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6114526A (en) * 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
BR9711098B1 (pt) 1996-07-01 2011-10-04 compostos heterocìclicos, processo para sua preparação e composições farmacêuticas contendo os mesmos e seu uso no tratamento de diabetes e doenças relacionadas.
US5885997A (en) * 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6011036A (en) * 1997-04-15 2000-01-04 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic hypolipidemic antihypertensive properties process for their preparation and pharmaceutical compositions containing them
US6011031A (en) * 1997-05-30 2000-01-04 Dr. Reddy's Research Foundation Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them
GB9711683D0 (en) * 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
GB9726563D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
GB9726566D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
BR0009934A (pt) 1999-04-23 2002-06-04 Smithkline Beecham Plc Produto farmacêutico
CN1379776A (zh) * 1999-08-17 2002-11-13 史密丝克莱恩比彻姆有限公司 包含噻唑烷二酮衍生物的药物组合物及其制备方法
WO2001090356A1 (fr) * 2000-05-25 2001-11-29 Yamanouchi Pharmaceutical Co., Ltd. Promoteur de pgc-1 humain
GB0019223D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
WO2006096398A2 (en) 2005-03-03 2006-09-14 Smithkline Beecham Corporation Medicaments
US20100099640A1 (en) 2007-05-04 2010-04-22 Joannes Geuns Tissue degeneration protection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
GB9023584D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
FR2680512B1 (fr) * 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH05310719A (ja) * 1992-04-28 1993-11-22 Terumo Corp チアゾリジン−２，４−ジオン誘導体

Also Published As

Publication number Publication date
CA2182986A1 (en) 1995-08-17
EP0777469A1 (en) 1997-06-11
SG47100A1 (en) 1998-03-20
AP553A (en) 1996-11-06
IL112590A (en) 2002-08-14
AU700826B2 (en) 1999-01-14
WO1995021608A1 (en) 1995-08-17
AP9500717A0 (en) 1995-04-30
IL112590A0 (en) 1995-06-29
AU1578395A (en) 1995-08-29
TW475896B (en) 2002-02-11
CN1083715C (zh) 2002-05-01
CN1145027A (zh) 1997-03-12
JPH09512249A (ja) 1997-12-09
CN1318372A (zh) 2001-10-24

Similar Documents

Publication Publication Date Title
MX9603338A (es) Uso de sensibilizadores a la insulina para tratar enfermedades renales.
MXPA02012763A (es) Combinaciones de inhibidores de dipeptidil peptidasa iv y otros agentes antidiabeticos para el tratamiento de diabetes mellitus.
PT867184E (pt) Utilizacao de tiagabina para o tratamento de desordens do sono
AP2001002291A0 (en) Novel method of treatment.
MXPA02002681A (es) Uso de metabolitos de acido alfa-linolenico para el tratamiento o prevencion del cancer.
HK1070575A1 (en) Use of botulinum toxin for treating cardiovasculardiseases
WO2002053101A3 (en) Method for treating fibrotic diseases or other indications
DK0880350T3 (da) Behandling af dissemineret sklerose
HK1073250A1 (en) Use of pleuromutilins for the treatment of disorders caused by helicobacter pylori
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
AU3308099A (en) Method for the treatment of pain, including chronic and female specific pain
AP9901720A0 (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitors.
EP1447090B8 (de) Verwendung von Hyaluronidase zur Prophylaxe und Behandlung von Herz-Kreislauf-Erkrankungen
IL154419A0 (en) The treatment of inflammatory disorders
WO2002067851A3 (en) Method for treating fibrotic diseases or other indications iiic
WO2000044408A3 (en) Method of treating demyelinating inflammatory disease using ccr1 antagonists
IL124870A0 (en) Nitric oxide (no) synthase inhibitor to treat or prevent type ii diabetes
EP0260790A3 (en) Use of pinacidil in the treatment of incontinence
MD1296F1 (en) The Nicolau method of treatment of the lichen planus
AP2000001959A0 (en) Treatment of generalized anxiety disorder with paroxetine.
AP2000001787A0 (en) Use of thiazolidinediones for the treatment of hyperglycaemia.
WO2002076405A3 (en) Compositions and methods of treatment of ulcerating diseases, burns, and related conditions